| Assessment Status |
Rapid Review complete |
| HTA ID |
24017 |
| Drug |
Alectinib |
| Brand |
Alecensa® |
| Indication |
As adjuvant treatment following complete tumour resection for adult patients with ALK-positive NSCLC at high risk of recurrence. |
| Rapid review commissioned |
24/05/2024 |
| Rapid review completed |
02/07/2024 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of alectinib for this indication compared with the current standard-of-care, on the basis of the proposed price relative to currently available therapies. |
